Hoth Therapeutics (HOTH) Competitors $1.20 -0.01 (-0.42%) As of 10:45 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HOTH vs. RPTX, CNTX, NRXP, GANX, IRD, VTGN, ANL, ZIVO, GNTA, and SNTIShould you be buying Hoth Therapeutics stock or one of its competitors? The main competitors of Hoth Therapeutics include Repare Therapeutics (RPTX), Context Therapeutics (CNTX), NRx Pharmaceuticals (NRXP), Gain Therapeutics (GANX), Opus Genetics (IRD), VistaGen Therapeutics (VTGN), Adlai Nortye (ANL), ZIVO Bioscience (ZIVO), Genenta Science (GNTA), and Senti Biosciences (SNTI). These companies are all part of the "pharmaceutical products" industry. Hoth Therapeutics vs. Its Competitors Repare Therapeutics Context Therapeutics NRx Pharmaceuticals Gain Therapeutics Opus Genetics VistaGen Therapeutics Adlai Nortye ZIVO Bioscience Genenta Science Senti Biosciences Hoth Therapeutics (NASDAQ:HOTH) and Repare Therapeutics (NASDAQ:RPTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends. Which has stronger valuation and earnings, HOTH or RPTX? Hoth Therapeutics has higher earnings, but lower revenue than Repare Therapeutics. Hoth Therapeutics is trading at a lower price-to-earnings ratio than Repare Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHoth TherapeuticsN/AN/A-$8.19M-$1.14-1.05Repare Therapeutics$53.48M1.16-$84.69M-$3.01-0.48 Which has more risk and volatility, HOTH or RPTX? Hoth Therapeutics has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Repare Therapeutics has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Is HOTH or RPTX more profitable? Repare Therapeutics' return on equity of -78.12% beat Hoth Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Hoth TherapeuticsN/A -109.18% -100.22% Repare Therapeutics N/A -78.12%-67.11% Does the media prefer HOTH or RPTX? In the previous week, Hoth Therapeutics and Hoth Therapeutics both had 1 articles in the media. Repare Therapeutics' average media sentiment score of 0.62 beat Hoth Therapeutics' score of 0.21 indicating that Repare Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hoth Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Repare Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in HOTH or RPTX? 7.1% of Hoth Therapeutics shares are owned by institutional investors. Comparatively, 85.1% of Repare Therapeutics shares are owned by institutional investors. 6.9% of Hoth Therapeutics shares are owned by company insiders. Comparatively, 11.5% of Repare Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer HOTH or RPTX? Hoth Therapeutics presently has a consensus target price of $4.00, indicating a potential upside of 234.73%. Repare Therapeutics has a consensus target price of $4.50, indicating a potential upside of 211.42%. Given Hoth Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Hoth Therapeutics is more favorable than Repare Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hoth Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Repare Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryRepare Therapeutics beats Hoth Therapeutics on 8 of the 14 factors compared between the two stocks. Get Hoth Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HOTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOTH vs. The Competition Export to ExcelMetricHoth TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.72M$2.90B$5.50B$9.00BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-1.0421.2326.5720.02Price / SalesN/A280.33415.46120.95Price / CashN/A41.4736.1356.90Price / Book1.397.498.065.50Net Income-$8.19M-$55.05M$3.15B$248.50M7 Day Performance2.14%2.58%1.72%2.61%1 Month Performance29.92%5.22%3.92%5.42%1 Year Performance33.50%5.04%35.02%20.76% Hoth Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOTHHoth Therapeutics1.8887 of 5 stars$1.20-0.4%$4.00+234.7%+35.9%$15.72MN/A-1.044RPTXRepare Therapeutics2.5165 of 5 stars$1.39flat$4.50+223.7%-55.6%$59.62M$53.48M-0.46180Positive NewsCNTXContext Therapeutics3.51 of 5 stars$0.66-0.8%$5.50+739.4%-65.7%$59.22MN/A-2.117NRXPNRx Pharmaceuticals2.0435 of 5 stars$3.26-4.7%$28.50+774.2%+27.7%$59.13MN/A-1.622GANXGain Therapeutics3.1017 of 5 stars$1.80-8.6%$8.20+355.6%+36.8%$58.99M$50K-2.0920Positive NewsIRDOpus Genetics1.6623 of 5 stars$0.94-3.5%$7.33+678.4%N/A$58.26M$10.99M-0.4514Gap DownVTGNVistaGen Therapeutics2.0361 of 5 stars$2.00+1.5%N/A-38.7%$57.44M$490K-1.2040ANLAdlai Nortye1.9614 of 5 stars$1.47-5.2%$9.00+512.2%-53.8%$57.20M$5M0.00127ZIVOZIVO Bioscience0.259 of 5 stars$14.91flatN/A+53.5%$56.85M$15.85K-3.0610GNTAGenenta Science2.5022 of 5 stars$3.05-1.6%$25.00+719.7%+24.8%$56.70MN/A0.007Gap DownSNTISenti Biosciences2.7584 of 5 stars$2.11-2.3%$8.50+302.8%-43.3%$56.33M$2.56M-0.194Gap Up Related Companies and Tools Related Companies Repare Therapeutics Alternatives Context Therapeutics Alternatives NRx Pharmaceuticals Alternatives Gain Therapeutics Alternatives Opus Genetics Alternatives VistaGen Therapeutics Alternatives Adlai Nortye Alternatives ZIVO Bioscience Alternatives Genenta Science Alternatives Senti Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HOTH) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hoth Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hoth Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HOTH Stock Alerts